Anus, Bones and Joints, Brain and Nervous System, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Other Hematopoietic, Phase I, Pediatrics, Unknown Sites, Breast, Cervix, Urinary BladderA Phase 1a/1b Study of LY3405105 Administered to Patients with Advanced Solid TumorsPrincipal Investigator: Patricia LoRusso
Breast Cancer
- BreastA Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).Principal Investigator: Erin Hofstatter
- Breast - Female, Breast - Male, BreastA Phase 1 Multi-Center Trial of Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to TrastuzumabPrincipal Investigator: Lajos Pusztai
- BreastA Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1Principal Investigator: Zia Rahman
- Anus, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Pancreas, Prostate, Rectum, Small Intestine, Stomach, Thyroid, Phase I, Breast, Urinary BladderA Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsPrincipal Investigator: Joseph Kim